PROJECT SUMMARY/ABSTRACT
Adhesion G protein-coupled receptors (aGPCRs) are a group of 33 poorly characterized non-olfactory GPCRs
with distinct features including autocatalytic processing and large extracellular regions. aGPCRs are involved
in a myriad of biological processes and some of them are associated with diseases, especially a wide range of
cancers. The extracellular regions of many of the aGPCRs contain domains that are known to be involved in
protein-protein interactions, suggesting that binding to cell surface protein ligands may play an important role in
their mechanisms of action. The majority of aGPCRs, however, are orphan receptors without known ligands.
Identification of ligands for these aGPCRs should help understand their physiological functions and roles in
cancer development. A major challenge for identifying ligands involved in ligand-receptor interactions at the
cell-cell interface is that they tend to bind their receptors very weakly and currently available methods do not
have enough sensitivity. To overcome this, we propose to employ a novel and highly sensitive cell-based
approach to identify protein ligands for 17 understudied orphan aGPCRs. The feasibility of the approach has
been tested using model ligands and receptors that are known bind to each other with low affinities. We will
use the cell-based approach to screen a collection of transmembrane proteins to identify ligand candidates for
the aGPCRs. Ligand candidates identified in this study will pave the way for more in-depth characterization of
their bindings to respective aGPCRs and the functional consequences of the bindings in future studies.
Public Health Relevance Statement
PROJECT NARRATIVE
We propose to identify the potential binding partners for understudied adhesion GPCRs using a highly
sensitive cell-based approach. The results will aid the understanding of their mechanism of action and help
develop therapeutics that target these receptors, many of which are involved in human diseases including
cancer.
National Center for Advancing Translational Sciences
CFDA Code
310
DUNS Number
038004941
UEI
ETGMYV7CKAJ7
Project Start Date
01-June-2022
Project End Date
31-May-2025
Budget Start Date
01-June-2022
Budget End Date
31-May-2025
Project Funding Information for 2022
Total Funding
$142,000
Direct Costs
$100,000
Indirect Costs
$42,000
Year
Funding IC
FY Total Cost by IC
2022
NIH Office of the Director
$142,000
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1R03TR004206-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R03TR004206-01
Patents
No Patents information available for 1R03TR004206-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R03TR004206-01
Clinical Studies
No Clinical Studies information available for 1R03TR004206-01
News and More
Related News Releases
No news release information available for 1R03TR004206-01
History
No Historical information available for 1R03TR004206-01
Similar Projects
No Similar Projects information available for 1R03TR004206-01